Xylocaine

For of women many years, the intrauterine device (IUD) has been a contraceptive choice for women. In 1995, the IUD was used by 11.9 percent of reproductive age worldwide, but by only 1.5 percent of women in North America. (1) A potential reason for this difference in use is the negative perception of IUDs created as a result of complications associated with the Dalkon Shield.

The Dalkon Shield was an IUD introduced in 1970 and recalled in 1975. It was associated with a significant incidence of pelvic inflammatory disease (PID) because its multifilament threads were believed to be prone to transmitting bacteria into the uterus and fallopian tubes.

Today, two IUDs are approved for use in the United States: a copper-releasing device (ParaGard) and a hormone-releasing device (Mirena). Both IUDs have monofilament threads that minimize the risk for bacteria transmission.

The copper-releasing IUD (Figure 1) is a T-shaped polyethylene device with 380 [mm.sup.2] of exposed surface area of copper on its arms and stem. The released copper ions interfere with sperm mobility and incite a foreign-body reaction that results in a spermicidal environment. (2) Barium sulfate has been added to the polyethylene substrate to make the device radiopaque. A 3-mm plastic ball is located at the base of the IUD, through which the monofilament thread passes. Once inserted, the IUD can remain in place for up to 10 years.

[FIGURE 1 OMITTED]

The hormone-releasing IUD (Figure 2) is a radiopaque T-shaped device with 52 mg of levonorgestrel on its arms and stem. The progestin is released at a rate of 20 mcg a day. Levonorgestrel is thought to thicken cervical mucus, creating a barrier to sperm penetration through the cervix, and it may stop ovulation and thin the uterus lining. Once inserted, the IUD can remain in place for up to five years.

[FIGURE 2 OMITTED]

Data are conflicting on which mechanism primarily is responsible for efficacy of IUDs. The results of a recent review indicated that pre- and post-fertilization mechanisms of action play a role in both IUDs. (3) [Evidence level B, systematic review of studies] The copper-releasing IUD and the hormone-releasing IUD have been shown in clinical trials to be 99.2 percent and 98 percent effective, respectively, in preventing pregnancy in one year of typical use. (4,5)

The contraceptive effects of the IUD are reversible after removal. The results of a recent study suggest that long-term IUD use (i.e., more than 78 months [6.5 years]) may be associated with an increased risk for fertility impairment. (6) [Evidence level C, prospective cohort study] Recommended Patient Profile and Contraindications

IUDs are for parous women who are in a stable, mutually monogamous relationship, with no history of PID. Although not contraindicated in this group, nulliparous women tend to have higher expulsion and failure rates, and also offer more challenging insertion because they have a smaller uterine cavity. (7)

Women exposed to sexually transmitted diseases (STDs) have a greater chance of developing PID. A history of PID suggests a risk for reinfection, although a remote history does not totally preclude choosing an IUD. A World Health Organization scientific working group concluded that women who have been pregnant after an occurrence of PID and are not currently at risk for infection can be candidates for IUDs. (1)

The hormone-releasing IUD may benefit women with anemia, menorrhagia, or dysmenorrhea. (8) While there is a greater risk for spotting or irregular bleeding during the first three months after insertion of this device, the risk decreases significantly at 12 months post-insertion. (9)

Both IUDs are classified as pregnancy category X. Contraindications are summarized in Table 1. (4,5,7,10,11)

Precautions

IUDs may be inserted anytime during the menstrual cycle. Documentation of a negative pregnancy test is prudent. Insertion may be performed during menstruation to provide additional reassurance that the woman is not pregnant.

If insertion is planned during the luteal phase, another nonhormonal contraceptive should be used until after the next menses. A pregnancy test can be done, but the patient should be made aware that a pregnancy test at this time cannot always rule out early pregnancy.

An IUD should not be inserted in a woman with an STD. The American College of Obstetricians and Gynecologists recommends a pelvic examination before insertion to screen for Chlamydia and gonorrhea. (12) [Evidence level C, consensus/expert guidelines]

Routine prophylactic antibiotic administration is not necessary. (13) [Evidence level A, high-quality meta-analysis] Studies have demonstrated that the use of prophylactic antibiotics at the time of IUD insertion provides little, if any, benefit. Doxycycline (Vibramycin) or erythromycin may be used for prophylaxis. (10,12)

According to the American Heart Association, antibiotic prophylaxis in patients at risk for endocarditis is not necessary before IUD insertion or removal. (14) [Evidence level C, expert/consensus guidelines]

Patient Preparation

The physician should discuss with the patient the risks and benefits of the IUD and, if necessary, other forms of contraception. The patient should review the manufacturer's patient information materials and have the opportunity to discuss with her physician any concerns. Informed consent may be obtained after these steps are completed.

Administration of a nonsteroidal anti-inflammatory drug (e.g., 600 to 800 mg of ibuprofen [Motrin]) one hour before insertion may alleviate discomfort. The physician should instruct the patient about how to locate the IUD threads. It is necessary for the woman to locate the threads to verify the position of the IUD after each menstruation. The patient should be told to call her physician's office if she is ever unable to locate the IUD threads.

Insertion

COPPER-RELEASING IUD

The proper equipment (Table 2) should be assembled before the procedure. Then, a bimanual examination with nonsterile gloves should be performed to determine the position of the uterus.

The arms of the IUD are to be folded into the insertion tube far enough to retain them. This can be done before the start of the procedure, working through the sterile package (Figure 3).

[FIGURE 3 OMITTED]

Sterile technique, including sterile gloves, is necessary during the procedure to minimize the risk of contamination or infection. The cervix and adjacent vaginal fornices should be cleansed liberally with an antiseptic solution. Chlorhexidine gluconate (Hibiclens) may be used if the patient is allergic to iodine.

The physician should stabilize the cervix during the insertion of the IUD with a tenaculum. Local anesthesia, such as 5 percent lidocaine gel (Xylocaine) placed in the cervical canal, or a paracervical block may be used to minimize discomfort.

A sterile uterine sound should be used to determine the depth of the uterine cavity. Contact with the vagina or speculum blades should be avoided. The uterine sound has a bulbous tip to help prevent perforation. An alternative to the uterine sound is an endometrial aspirator such as those used for endometrial biopsy sampling. An adequate uterine depth is between 6 and 9 cm and should be documented in the patient's record. An IUD should not be inserted if the depth of the uterus is less than 6 cm.

The physician should use sterile gloves to remove the IUD from the sterile package. The blue flange should be aligned with the IUD arms and set at the distance the uterus was sounded. The white inserter rod should then be placed into the insertion tube at the end opposite the arms of the IUD and approximated against the ball at the base of the IUD.

The physician should then insert the IUD into the uterus until the flange is against the cervical os. The clear inserter tube should be pulled back on the insertion rod approximately 2 cm so that the arms can spread to the "T" position (Figure 4). The tube should be advanced slowly to ensure a correct positioning of the IUD (Figure 5). The physician should remove the insertion rod by holding the insertion tube in place (Figure 6) and then remove the insertion tube and the tenaculum. Finally, the threads emerging from the cervical os should be cut to a length of 3 cm. The length of the threads in the vagina should be noted in the patient's record for further reference.

[FIGURES 4-6 OMITTED]

HORMONE-RELEASING IUD

As with the copper-releasing IUD, the proper equipment (Table 2) for insertion of the hormone-releasing IUD should be assembled before the procedure. Then, a bimanual examination with nonsterile gloves should be done to determine the position of the uterus. Sterile technique with sterile gloves is necessary during the procedure itself to minimize the risk of contamination or infection. The cervix and adjacent vaginal mucosa should be cleansed liberally with an antiseptic solution. Chlorhexidine gluconate may be used if the patient is allergic to iodine.

The physician should stabilize the cervix during the insertion of the IUD with a tenaculum. Local anesthesia, such as 5 percent lidocaine gel placed in the cervical canal, or a paracervical block may be used to minimize discomfort.

A sterile uterine sound or an endometrial aspirator should be used to determine the depth of the uterine cavity. Contact with the vagina or speculum blades should be avoided. An adequate uterine depth is between 6 and 9 cm and should be documented in the patient's record. An IUD should not be inserted if the depth of the uterus is less than 6 cm.

The physician should open the sterile IUD package, put on sterile gloves, pick up the inserter containing the IUD, and carefully release the threads from behind the slider, allowing them to hang freely. The slider should be positioned at the top of the handle nearest the IUD. While looking at the insertion tube, the physician should check that the arms of the device are horizontal. If not, they must be aligned using sterile technique (Figure 7). The physician should pull on both threads to draw the IUD into the insertion tube so that the knobs at the end of the arms cover the open end of the inserter (Figure 8). The threads should be fixed tightly in the cleft at the end of the handle (Figure 9), and the flange should be set to the depth measured by the sound (Figure 10).

[FIGURES 7-10 OMITTED]

The physician should insert the IUD by holding the slider firmly at the top of the handle and gently placing the inserter into the cervical canal. The insertion tube should be advanced into the uterus until the flange is situated at a distance of about 1.5 to 2 cm from the external cervical os, allowing ample space for the IUD arms to open. While holding the inserter steady, the physician should release the arms of the IUD by pulling the slider back until the top of the slider reaches the raised horizontal line on the handle (Figure 11). The inserter should be pushed gently into the uterine cavity until the flange touches the cervix.

[FIGURE 11 OMITTED]

The IUD should now be positioned at the top of the fundus. The physician then releases the IUD by pulling the slider all the way down while holding the inserter firmly in position. The threads will be released automatically (Figure 12). The inserter should be removed from the uterus. Finally, the threads emerging from the cervical os should be cut to a length of 2 to 3 cm. The length of the threads in the vagina should be noted in the patient's record for further reference.

[FIGURE 12 OMITTED]

The manufacturers of both IUDs have created practice kits that can help physicians learn to insert an IUD.

Adverse Effects

Following insertion of either device, a follow-up appointment should be planned after the next menses to address any concerns or adverse effects, ensure the absence of infection, and check the presence of the strings.

The most common adverse effects of IUDs are cramping, abnormal uterine bleeding, and expulsion (Table 3). (4,5,7,11,12) Adverse effects related specifically to the hormone-releasing IUD include amenorrhea, acne, depression, weight gain, decreased libido, and headache. First-year failure rates are reported to be between 1 and 2 percent. (1)

If the IUD threads are ever not present, a pregnancy test should be performed. When the results are negative, a cytobrush can be inserted gently into the cervical canal to locate the threads. If this method is unsuccessful, radiography or ultrasonography may be used to locate the IUD. Uterine perforation, which is more likely to occur during insertion of the device, ranges from 0.1 to 0.3 percent. (11)

When the results of the pregnancy test are positive, an ectopic implantation must be ruled out. If the strings are visible and the pregnancy is early, the IUD can be removed but with a risk of pregnancy loss. If the strings are not visible, ultrasonography should be performed to identify the IUD for removal.

Removal

An IUD should be removed at the expiration date, when the patient develops a contraindication, when adverse effects do not resolve, or on patient request. Treatment for cervical dysplasia may be different with the IUD present. Colposcopy may be performed, but the IUD should be removed if an excisional procedure is performed.

The IUD is removed by securely grasping the threads at the external os with ring forceps. Traction should be applied away from the cervix. If resistance is met, the removal should be abandoned until it is determined why the IUD is not moving. A deeply embedded IUD may have to be removed hysteroscopically.

The author thanks Kaydance Kerrick for assistance with the preparation of the manuscript.

REFERENCES

(1.) IUDs--an update. Popul Rep B 1995;(6):1-35.

(2.) Spinatto JA 2d. Mechanism of action of intrauterine contraceptive devices and its relation to informed consent. Am J Obstet Gynecol 1997;176:503-6.

(3.) Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of post-fertilization effects. Am J Obstet Gynecol 2002;187:1699-708.

(4.) Mirena [package insert]. Montville, N.J.: Berlex Laboratories, 2003.

(5.) ParaGard [package insert]. Tonawanda, N.Y.: FEI Products, 2003.

(6.) Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG 2001;108:304-14.

(7.) Nelson AL. The intrauterine contraceptive device. Obstet Gynecol Clin North Am 2000;27:723-40.

(8.) Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-21.

(9.) Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.

(10.) Physicians' Desk Reference. 58th ed. Montvale, N.J.: Thomson PDR, 2004.

(11.) Canavan TP. Appropriate use of the intrauterine device. Am Fam Physician 1998;58:2077-84,2087-8.

(12.) American College of Obstetricians and Gynecologists. The intrauterine device. ACOG technical bulletin no. 164. Washington, D.C.: ACOG, 1992.

(13.) Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Data-base Syst Rev 2001;(1):CD001327. Update in: Cochrane Database Syst Rev 2001;(2):CD001327.

(14.) Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997;96:358-66.

BRETT ANDREW JOHNSON, M.D., is program director of the Methodist Health System of Dallas Family Practice Residency at Methodist Charlton Medical Center, Dallas. He also is an associate professor of family and community medicine at the University of Texas Southwestern Medical School, Dallas. He received his medical degree from the State University of New York School of Medicine, Buffalo, and completed a residency in family medicine at Hamot Family Practice Residency Program, Erie, Pa.

Address correspondence to Brett A. Johnson, M.D., Methodist Charlton Medical Center, 3500 W. Wheatland Rd., Dallas, TX 75237. Reprints are not available from the author.

The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group